Telix and Regeneron Announce Strategic Radiopharma Collaboration
![]() |
- Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model.
- Collaboration combines Telix's expertise in radiopharmaceutical development and manufacturing with Regeneron's leading antibody discovery/development platforms and oncology experience.
- Telix to receive US$40...
Read more: Telix and Regeneron Announce Strategic Radiopharma Collaboration





